Bemgaluru: Mango Sciences, Inc., a Boston and Bengaluru-based data and AI company, has entered into a strategic partnership with Mumbai-headquartered ImmunoAdoptive Cell Therapy (ImmunoACT) to enhance affordability and access to NexCAR19, its CAR-T therapy for patients with leukaemia and lymphoma in India.
Under this partnership, ImmunoACT will be able to offer eligible patients a structured bridge financing programme and a value-based offering for NexCAR19, enabling wider access to CAR-T therapy.
The initiative introduces 0% interest EMI plans of up to ₹10 lakhs to help patients manage treatment costs. In addition, clinically eligible patients may also avail a value-based benefit of up to ₹10 lakhs, linked to outcomes.
Also Read: Goa: Rasayu Cancer Clinic Partners with Gomantak Ayurveda Mahavidyalaya for Cancer Research
NexCAR19 Financing and Value-Based Access Programme
NexCAR19 is a first-of-its-kind, indigenously developed CAR-T therapy that has enabled patients in India to access advanced cancer treatment at a significantly more affordable cost.
Through the collaboration with Mango Sciences, the partners aim to further increase the reach of NexCAR19 among patients who require this potentially life-saving therapy.
Initially, the Mango Sciences benefit programme associated with NexCAR19 will be available at select healthcare facilities across the country for patients undergoing ImmunoACT’s CAR-T treatment.
Commenting on the partnership, Dr Mohit Misra, Founder and CEO of Mango Sciences, said that the collaboration marks a global first in introducing value-based offerings for CAR-T therapy.
Also Read: Alkem launches Pertuza biosimilar in India for HER2-positive breast cancer treatment
He highlighted that data science and technology will be leveraged to ensure patients can access cutting-edge oncology innovations, while working alongside ImmunoACT to improve cancer outcomes through wider access to therapies such as CAR-T.
Dr Rahul Purwar, Founder of ImmunoACT, stated that the partnership with Mango Sciences is aimed at improving access and affordability for patients requiring NexCAR19.
He noted that the outcome-based programmes reflect ImmunoACT’s confidence in the efficacy and safety of NexCAR19, while providing meaningful financial support to patients and their families.
